DMAC

DiaMedica Therapeutics Inc

8.63

Oct 22 • 3:59 PM ET -0.06 (-0.69%)

8.63

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: MIST VCRE PROK TECX TENX CALC TVTX UNCY CVKD DWTX

| Held by: IWM IWO VXF VTWO IWC VTWG RSSL VTHR ITWO URTY

Scroll to Statements

Index	RUT
Market Cap	465.37M
Enterprise Value	422.05M
Income	-37.54M
Sales	0.00M
Book/sh	0.71
Cash/sh	0.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	35
IPO	Jan 04, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	12.14
P/C	10.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.72
Current Ratio	6.72
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.71
EPS next Y	-0.75
EPS next Q	-0.21
EPS this Y	-10.00%
EPS next Y	2.92%
EPS next 5Y	-9.82%
EPS past 3/5Y	-10.48% 2.31%
Sales past 3/5Y	- -
EPS Y/Y TTM	-3.42%
Sales Y/Y TTM	-
EPS Q/Q	-4.97%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	5.43% -

Insider Own	43.33%
Insider Trans	0.00%
Inst Own	18.44%
Inst Trans	1.62%
ROA	-98.18%
ROE	-114.62%
ROIC	-97.75%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.67%
SMA50	17.99%
SMA200	21.79%
Trades

Shs Outstand	53.93M
Shs Float	30.56M
Short Float	18.26%
Short Ratio	30.67
Short Interest	5.58M
52W High	10.42 -17.17%
52W Low	5.24 64.54%
Volatility	7.41% 6.38%
ATR (14)	0.48
RSI (14)	62.18
Beta	0.96
Rel Volume	0.48
Avg Volume	181.93K
Volume	87,993

Perf Week	7.34%
Perf Month	14.15%
Perf Quarter	28.14%
Perf Half Y	38.75%
Perf YTD	8.42%
Perf Year	28.61%
Perf 3Y	301.40%
Perf 5Y	114.68%
Perf 10Y	118.81%
Recom	1.00
Target Price	15.50
Prev Close	8.69
Price	8.63
Change %	-0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-25	Resumed	Cantor Fitzgerald	Overweight
Oct-30-25	Initiated	TD Cowen	Buy
Oct-07-24	Initiated	H.C. Wainwright	Buy	$7
Apr-24-24	Resumed	Craig Hallum	Buy	$8
Jun-22-23	Upgrade	Oppenheimer	Perform → Outperform	$7
Apr-09-21	Initiated	Oppenheimer	Outperform	$27
Feb-17-21	Initiated	ROTH Capital	Buy	$38
Oct-30-20	Initiated	Guggenheim	Buy	$16
Jul-08-20	Initiated	Maxim Group	Buy	$14
Apr-30-19	Initiated	Dougherty & Company	Buy	$8
Mar-05-19	Initiated	Lake Street	Buy	$9

Show Previous Ratings

Today 08:00AM	DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial (Business Wire)
Oct-19-26 08:00AM	DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar (Business Wire)
Sep-30-26 08:30AM	DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results (Business Wire)
Sep-02-26 08:30AM	DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences (Business Wire)
Aug-11-26 03:01PM	DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... (GuruFocus.com)
01:26PM	Loading…
01:26PM	DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-10-26 04:30PM	DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights (Business Wire)
Aug-04-26 04:30PM	DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 (Business Wire)
Jul-17-26 04:30PM	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-23-26 08:30AM	DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction (Business Wire) +6.62%
Jun-16-26 08:30AM	DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program (Business Wire)
May-27-26 04:30PM	DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 (Business Wire)
May-20-26 08:30AM	DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial (Business Wire)
May-12-26 04:15PM	DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-06-26 04:30PM	DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights (Business Wire)
08:25AM	Loading…
Apr-30-26 08:25AM	DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 (Business Wire)
Mar-31-26 03:01PM	DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
12:40PM	DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-30-26 04:45PM	DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights (Business Wire)
Mar-23-26 08:25AM	DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 (Business Wire) +7.84%
Mar-05-26 07:35AM	DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia (Business Wire)
Feb-24-26 09:23AM	DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences (Business Wire)
Jan-16-26 05:00PM	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -11.30%
Dec-18-25 08:45AM	DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA (Business Wire)
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Nov-20-25 01:50PM	3 Biotech Stocks Wall Street Analysts Predict Will More Than Double (Barchart)
Nov-14-25 09:38AM	Microsoft initiated, Home Depot downgraded: Wall Street's top analyst calls (The Fly) +9.41%
Nov-13-25 02:05PM	DiaMedica Therapeutics Inc (DMAC) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... (GuruFocus.com) -14.10%
Nov-12-25 04:30PM	DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights (Business Wire)
Nov-10-25 08:15AM	DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (Business Wire)
04:15PM	Loading…
Nov-06-25 04:15PM	DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 (Business Wire) -6.47%
Sep-29-25 04:15PM	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Sep-17-25 12:00PM	DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-09-25 09:55AM	After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright (Zacks)
Sep-08-25 05:04PM	Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade (Zacks) +16.61%
Sep-05-25 08:30AM	DiaMedica Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +14.34%
Sep-02-25 08:23AM	DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference (Business Wire) -6.83%
Aug-28-25 12:00PM	What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-19-25 09:55AM	Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? (Zacks)
Aug-12-25 04:15PM	DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (Business Wire) +13.97% +14.94%
Aug-06-25 08:00AM	DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer (Business Wire) +5.12%
Aug-05-25 04:15PM	DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 (Business Wire)
Jul-23-25 04:30PM	DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement (Business Wire) +11.96% -5.24%
Jul-21-25 08:00AM	DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline (Business Wire) +8.61%
Jul-17-25 08:00AM	DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer (Business Wire)
Jun-24-25 08:30AM	DiaMedica Therapeutics Announces Inclusion in the Russell 2000 and Russell 3000 Indexes (Business Wire)
May-22-25 08:30AM	DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 (Business Wire)
May-19-25 09:00AM	DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia (Business Wire)
May-15-25 03:09AM	DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
May-14-25 11:14PM	Q1 2025 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
04:30PM	DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference ESOC 2025 (Business Wire)
May-13-25 04:30PM	DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights (Business Wire)
May-08-25 04:00PM	DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May (Business Wire)
May-07-25 08:30AM	DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025 (Business Wire)
Apr-15-25 08:54PM	DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve (Seeking Alpha)
Mar-19-25 03:00AM	DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Mar-18-25 10:22PM	Q4 2024 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.02%
Mar-17-25 04:30PM	DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results (Business Wire)
Mar-11-25 08:23AM	DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 (Business Wire)
Feb-24-25 08:30AM	DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors (Business Wire)
Feb-20-25 08:15AM	DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke (Business Wire)
Feb-10-25 04:15PM	DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-03-24 08:25AM	DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia (Business Wire)
Nov-15-24 02:06AM	Q3 2024 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-24 04:20PM	DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results (Business Wire)
04:05PM	DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia (Business Wire)
Nov-12-24 08:23AM	DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference (Business Wire)
Nov-06-24 08:32AM	DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 (Business Wire)
Oct-10-24 05:28AM	DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial (Clinical Trials Arena)
Oct-09-24 08:27AM	DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia (Business Wire)
Sep-04-24 04:15PM	DiaMedica Therapeutics Upcoming Conference Participation (Business Wire)
Aug-07-24 04:15PM	DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 09:40AM	Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? (Zacks) +5.18%
08:20AM	DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 (Business Wire)
Jul-11-24 08:00AM	DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia (Business Wire) +6.67%
Jul-01-24 08:00AM	DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement (Business Wire)
Jun-26-24 08:15AM	DiaMedica Therapeutics Announces $11.8 Million Private Placement (Business Wire) +30.97%
08:00AM	DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia (Business Wire)
May-13-24 12:08PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 10:54PM	DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19% -6.34%
04:30PM	DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results (Business Wire)
May-02-24 08:55AM	DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 (Business Wire)
Apr-18-24 10:06AM	DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch (Zacks)
Apr-17-24 04:08PM	DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke (Business Wire) +9.70%
Apr-15-24 09:35AM	DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-23-24 06:00AM	Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-19-24 09:53PM	DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 (InvestorPlace)
04:15PM	DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results (Business Wire)
Jan-29-24 04:13PM	DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference (Business Wire)
Jan-22-24 08:23AM	DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer (Business Wire)
Dec-04-23 02:56PM	Billionaire Lee Coopermans 10 Stock Picks with Huge Upside Potential (Insider Monkey)
Nov-15-23 12:15PM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 10:54PM	Q3 2023 DiaMedica Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
02:53PM	DiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
Nov-13-23 04:28PM	DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results (Business Wire)
Nov-09-23 08:25AM	DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023 (Business Wire)
Nov-06-23 08:23AM	DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023 (Business Wire)
Sep-12-23 08:13AM	DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer (Business Wire)
Sep-06-23 08:35AM	DiaMedica Therapeutics to Participate at Lake Streets 7th Annual Best Ideas Growth Conference (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STAHLBERG JAN	10% Owner	Nov 19 '25	Buy	7.21	240,352	1,732,361	8,375,092	Dec 08 05:15 PM
STAHLBERG JAN	10% Owner	Nov 21 '25	Buy	7.41	208,872	1,547,574	8,712,390	Dec 08 05:15 PM
STAHLBERG JAN	10% Owner	Nov 18 '25	Buy	6.75	182,882	1,234,618	8,134,740	Dec 08 05:15 PM
STAHLBERG JAN	10% Owner	Nov 17 '25	Buy	6.52	187,393	1,221,165	7,951,858	Dec 08 05:15 PM
STAHLBERG JAN	10% Owner	Nov 20 '25	Buy	7.41	128,426	951,213	8,503,518	Dec 08 05:15 PM
STAHLBERG JAN	10% Owner	Nov 25 '25	Buy	8.57	73,099	626,817	8,825,742	Dec 08 05:15 PM
STAHLBERG JAN	10% Owner	Nov 24 '25	Buy	7.89	40,253	317,721	8,752,643	Dec 08 05:15 PM
Parsons James T.	Director	Nov 21 '25	Option Exercise	2.20	12,000	26,400	87,854	Nov 25 04:30 PM

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

PresidentMr. Dietrich John Pauls MBA

CFO & Corporate SecretaryMr. Scott Kellen CPA

Chief Medical OfficerDr. Julie Krop M.D.

Chief Technology OfficerDr. Ambarish Shah Ph.D.

Chief Commercial OfficerMr. Dominic R. Cundari

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DMAC

DiaMedica Therapeutics Inc

Upgrade your Finviz experience